Section Arrow
NVCR.NASDAQ
- NovoCure Limited
Quotes are at least 15-min delayed:2025/06/28 15:19 EDT
Last
 18
+0.9 (+5.26%)
Day High 
18.04 
Prev. Close
17.1 
1-M High
20.06 
Volume 
3.42M 
Bid
17.73
Ask
18.18
Day Low
17.02 
Open
17.19 
1-M Low
16.19 
Market Cap 
1.91B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 17.26 
20-SMA 17.4 
50-SMA 17.55 
52-W High 34.13 
52-W Low 14.17 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.51/-1.92
Enterprise Value
2.02B
Balance Sheet
Book Value Per Share
3.25
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
605.22M
Operating Revenue Per Share
4.52
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
AMIXAutonomix Medical Inc2.01+0.76+60.80%-- 
NAOVNanoVibronix Inc1.17+0.3009+34.62%-- 
BFLYButterfly Network1.96-0.06-2.97%-- 
BBLGBone Biologics Corp4.58+0.42+10.10%0.08PE
BSXBoston Scientific Corp106.53+1.95+1.86%76.05PE
Quotes are at least 15-min delayed:2025/06/28 15:19 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.